Poland· PL-100462352
Ultomiris
A ravulizumab product containing ravulizumabum, registered in Poland by Alexion Europe SAS.
Checked against URPL (Poland) on
Informational only — not a medical device.
The record
At a glance
URPL (Poland)- Active substance
- Ravulizumabum
- Manufacturer
- Alexion Europe SAS
- Country
- Poland (PL)
- ATC code
- L04AA43
- ATC class
- Ravulizumab
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 4
- gtin05391527740179
- gtin05391527744436
- gtin05391527740162
- gtin05391527744429
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
2 interactions on record for ravulizumab.
Graded by severity as the source publishes them — 2 minor. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ravulizumab · interactions on record
2 records
Same medicine, other countries
Ravulizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayUltomirisAlexion Europe SAS (2)
- SwedenUltomiris 1100 mg/11 ml Koncentrat till infusionsvätska, lösningAlexion Europe SAS
- FinlandUltomirisAlexion Europe SAS
- BelgiumUltomiris 1100 mg/11 mlAlexion Europe
- CzechiaULTOMIRISAlexion Europe SAS, Levallois-Perret
- IrelandUltomiris 300 mg/3 mL concentrate for solution for infusionAlexion Europe S.A.S.
- IcelandULTOMIRISAlexion Europe SAS
- United KingdomUltomiris 1,100mg/11ml concentrate for solution for infusion vialsAlexion Pharma UK Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ultomiris
- Liechtenstein · Ultomiris
- Norway · Ultomiris
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/49d3597c-16a5-4625-b892-81a5e77f1c88 GET /v1/drugs/49d3597c-16a5-4625-b892-81a5e77f1c88?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "100 mg/ml",
"packaging": "05391527740179 ¦ Rpz ¦ EU/1/19/1371/002 ¦ 142996\n1 fiol. 3 ml\n¦ UR/Z/4c/162/22 - 05391527744436\n05391527740162 ¦ Rpz ¦ EU/1/19/1371/003 ¦ 143838\n1 fiol. 11 ml\n¦ UR/Z/4c/168/22 - 05391527744429",
"substance": "Ravulizumabum 300 mg",
"common_name": "Ravulizumabum",
"pl_product_id": "100462352",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about ravulizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.